Summary.-Inbred rats were injected s.c. with cells of syngeneic hepatoma D23, D23 cells + BCG as a mixed inoculum, mixed inoculum one side and D23 alone contralaterally, or BCG alone. Their blood mononuclear cells were tested weekly for cytotoxicity against D23 target cells using a microcytotoxicity method and their serum was tested for blocking activity against cytotoxicity by lymph node cells from immunized rats.
IT is now well established that Bacillus Calmette Guerin (BCG) has marked antitumour properties, as demonstrated by studies with a wide variety of experimental tumours Pimm, 1971, 1974; Bartlett, Zbar and Rapp, 1972; Chassoux and Salomon, 1975; Moore, Lawrence and Nisbet, 1975; Simmons, Rios and Kersey, 1972) . It has been recognized that close contact between tumour cells and BCG often produces better tumour suppression than administration of the BCG at a site distant from the tumour cells, and this effect has been attributed largely to the host response to BCG itself rather than the tumour cells (Bartlett et al., 1972; Moore et al., 1975) . However, there is no doubt that an immune response to tumour cells also develops as a result of BCG-induced growth suppression, since rats which have rejected immunogenic tumours as a result of BCG treatment are resistant to further challenge with the same tumour (Baldwin and Pimm, 1973) .
Analysis of the tumour-immune response in BCG-treated animals can most conveniently be carried out by means of in vitro tests. Bansal and Sjogren (1973) have shown that a polyoma-virusinduced rat tumour could be inhibited if BCG was administered at the time of tumour grafting, and that treated animals developed an increased cellmediated immunity to the tumour demonstrable by a microcytotoxicity test. If, however, BCG was given after the appearance of a palpable tumour nodule, tumour growth was accelerated. This was accompanied by an increase in serum factors which " blocked " cell-mediated immunity, but there was no increase in direct cell-mediated immunity.
The following report is a study of the development of cell-mediated cytotoxicity and humoral blocking or inhibitory factors in rats treated with cells of an aminoazo-dye-induced hepatoma (D23) and BCG. This tumour can be suppressed by admixture of viable cells with BCG (Baldwin and Pimm, 1973) and its immunological behaviour has been well studied by in vitro cytotoxicity methods (Baldwin, Embleton and Robins, 1973; Baldwin, Price and Robins, 1973) . It was thus possible to set up experimental groups with a fairly predictable course of tumour development and to evaluate the immune response of individual rats over a period of time in order to attempt correlations between the host anti-tumour response and the behaviour of the tumour in response to BCG treatment.
MATERIALS AND METHODS
Animals.-Inbred Wistar rats were used. These rats accept skin grafts between individuals of the same sex and strain.
Tumours. Blocking factor assay.-D23 target cells were plated at 200/well and allowed to attach to the bottom of the wells. Lymph node cells (LNC) were prepared from control rats or rats immunized with 15,000 R -irradiated grafts of hepatoma D23, as previously described (Baldwin et al., 1973a) . These lymph node cells have been shown to react specifically against the immunizing tumour (Baldwin et al., 1973a; Zoller, Dickinson and Embleton, 1975) , and were therefore used to provide an effector cell preparation as near standard as possible. Blood plasma was isolated from the supernatant during the preparation of mononuclear cells from heparinized blood. Plasma from treated or control rats was diluted 1/5 in MEM and 0-05 ml aliquots were added to the target cells after removal of the supernatant medium. The cells were incubated for 45 min at 370C and 2 x 105 LNC were added in 0-2 ml MEM without removing the plasma. After a further 45 min calf serum was added to a concentration of 10% and the plates were incubated for 2 days at 370C. Percentage blocking was calculated by comparing the % cytotoxicity of immune LNC in the presence of test plasma with % cytotoxicity in the presence of control plasma as described previously (Baldwin et al., 1973a) .
RESULTS
Growth of D23 hepatoma cells was suppressed in all rats receiving a mixed inoculum of 5 X 104 tumour cells and 1 mg BCG, while the same dose of tumour cells alone grew progressively (Table I , Fig. 1 ). In animals receiving a mixed inoculum of tumour cells and BCG on one side and a simultaneous contralateral inoculum of D23 cells only, the contralateral inoculum grew more slowly than in rats not treated with BCG ( Fig. 1 ), but complete suppression was only observed in 1/11 animals ( Table I ). Table 1 ).
Cell-mediated cytotoxicity against D23 cells by blood mononuclear cells was observed on repeated occasions in all animals treated with tumour cells, whether or not the cells were suppressed by admixture with BCG (Table I) . Rats developing growing tumours had cytotoxic cells up to 35 days after inoculation, at which time the size of the tumours necessitated termination of the experiments (Fig. 2) . In rats whose tumour was completely suppressed by admixture with BCG, however, cytotoxicity gradually decreased after 7 days and levels detected after 28 days were insignificant (Fig. 2) inactivated by 60Co-irradiation (15,000 R) and these showed a similar decline of cytotoxicity after 7 days. Rats injected only with 1 mg BCG showed a low level of cytotoxicity at 7 days, but this was transient and no significant cytotoxicity was detectable at 14 days or later (Fig. 2) .
Serum blocking activity was also demonstrable in all rats developing growing tumours (Table I ), in agreement with previous studies on hosts bearing hepatoma D23 (Baldwin et al., 1973a) . This was detectable at 7 days and continued to be present up to 35 days, fairly constant levels giving around 80% to 90% blocking being observed throughout the time course. Rats not developing growing tumours did not have significant blocking activity at any stage, although a small insignificant degree of blocking appeared during the first 2 weeks (Fig. 3) . These animals included those whose tumour was inhibited by contact with BCG, rats treated with BCG alone and the single rat whose contralateral tumour inoculum was suppressed by an injection of tumour cells + BCG (Table I) . Of 4 rats whose contralateral tumour was deliberately prevented from growing by irradiation, blocking activity was observed in only one (Table I) .
Splenectomized rats
Tumours resulting from an injection of 5 X 104 D23 cells developed in splenectomized rats at a slightly faster rate than in intact or sham-operated controls, but in animals simultaneously given a mixed inoculum of BCG and tumour cells on the opposite flank the rate of growth was retarded (Fig. 4) , as in intact rats (Fig. 1) . Thus splenectomy had no influence on the weak immunotherapeutic effect of the mixed inoculum on the contralateral tumour.
Cell-mediated cytotoxicity was not impaired in splenectomized rats, being about 50% at Day 7 and continuing at about the same or a slightly increased level up to 28 days (Fig. 5 ). Splenectomized animals which had been given an inoculum of BCG and D23 cells in addition to contralateral tumour cells also had a moderately high level of cytotoxic mononuclear cells at 7 days, but this diminished to a fairly low level at 21-28 days (Fig. 5) .
Serum blocking activity was demonstrable in all groups, but it developed more slowly than in intact rats and did not reach their value until 14 days ( Fig. 6) all animals up to 28 days, although there was some decrease in the group treated with mixed BCG and tumour cell vaccine. The reduction of blocking activity in this group appeared later than the reduction of cytotoxicity (Fig. 5) which was also observed.
Specificity tests
Previous studies have indicated that cytotoxicity against rat hepatoma cells by lymph node cells from immunized or tumour-bearing animals is tumour-specific, with little cross-reaction between tumours with antigens shown to be distinct by transplantation tests (Baldwin et al., 1973a) . The specificity of action of mononuclear cells prepared from heparinized blood of animals bearing tumours developing from trypsinized cell suspensions is shown in Table II (Fig. 2) , and show that the cellmediated cytotoxicity seen against D23 throughout the later part of the time course was tumour-specific.
Serum-mediated blocking of cell-mediated immunity has also previously been reported to be specific for given tumours, using serum prepared from clotted blood of tumour-bearing animals (Baldwin et al., 1973a, b) . In the present study, however, plasma was isolated from heparinized blood in order to assay blocking activity in the same samples as were used for effector cell preparation. In order to test whether heparin produced nonspecific effects, a further series of crosstests were carried out as shown in Table   III .
Lymph node cells from immune donors were used as effector cells in the majority of the tests because these were known to be tumour-specific in activity (Baldwin et al., 1973a Table I (Figs. 2 and 5) were also subject to the blocking effects of humoral factors in tumour-bearing animals.
DISCUSSION
The growth of hepatoma D23 could be suppressed by admixture of tumour cells with BCG as previously reported (Baldwin and Pimm, 1973 Sjogren (1972, 1973) have shown that splenectomy in their system can lead to retardation or regression of tumours if combined with immune serum or BCG treatment.
Cell-mediated cytotoxicity developed in all rats treated with D23 tumour cells, whether or not these grew progressively or were suppressed by BCG treatment or y-irradiation. Animals with growing tumours exhibited strong cytotoxicity right up to the time of termination (5 weeks), while those with suppressed tumours showed a decline in cytotoxicity after 14 days although cytotoxic cells were still detectable up to 28 days after inoculation. The animals with BCG-suppressed tumours at no time showed stronger reactivity than those given tumour cells alone, contrary to the findings of Bansal and Sjogren (1973) who reported that cell-mediated cytotoxicity to polyoma tumours was increased in BCG-treated rats.
Animals treated with BOG alone showed a slight transient cell-mediated cytotoxicity at 7 days, which was not evident thereafter. This could have been due to the presence of activated monocytes in the mononuclear cell suspensions in the early stages after treatment, since it has been shown that BCG-primed macrophages are cytotoxic for tumour cells (Evans and Alexander, 1972) . No attempt had been made to separate monocytes from lymphocytes in the present studies, since it was felt that either cell type might act as an effector cell in the BCG immunotherapy model employed.
Serum factors blocking cell-mediated cytotoxicity were assayed with the test serum present during the whole period of incubation of effector cells with target cells, rather than by pretreatment of effector cells or target cells as in previous studies (Baldwin et al., 1973a, b) . Under these conditions, significant blocking was found in all animals which developed growing tumours, including both intact and splenectomized animals. Serum from rats bearing D23 tumour has previously been shown to contain factors which can block cytotoxicity when applied to the target cells (Baldwin et al., 1973a; Bowen, Robins and Baldwin, 1975) or to the effector cells (Baldwin et al., 1973b; Bowen et al., 1975) . In both situations the blocking effect has been attributed to complexes of tumour antigen and tumour-specific antibody, and inhibition at the effector cell level can also be accomplished by treatment with tumour antigen alone. Sjogren (1972, 1973) have interpreted the therapeutic effects of splenectomy in their polyoma rat tumour system on the basis of loss of blocking activity owing to the lack of circulating complexes resulting from reduced antibody-forming capability. In view of the time lag in blocking factor detection, there was no correlation between blocking measured in vitro and the slightly accelerated development of tumours in the splenectomized groups. Neither can the growth rate be explained on the basis of reduced cell-mediated immunity, since cell-mediated cytotoxicity was equally high in intact and splenectomized rats. In contrast to tumour-bearing rats, no blocking factor was detectable in rats which failed to develop tumours. This was not attributable to BCG treatment, since BCG-treated rats which grew contralateral tumours had considerable blocking activity, but was correlated only with the lack of growing tumours.
These studies were undertaken in order to ascertain whether any differences could be found in animals given BCG immunotherapy and/or splenectomy compared with normal tumour-bearing animals, correlated with tumour growth. This is an important concept in relation to current cancer immunotherapy trials in man, where attempts are being made to correlate the clinical course of the disease with in vitro measurements of tumour-directed immunity, as exemplified by trials with malignant melanoma (Berkelhammer et al., 1975; Currie, 1973; Currie and McElwain, 1975) . In the rat hepatoma system, where only weak immunotherapeutic effects were obtained, there was a strong correlation between tumour growth and serum blocking activity, but no correlation between BCG treatment and blocking factor development. Cell-mediated cytotoxicity was comparable in all groups of tumourtreated rats whether they received immunotherapy, splenectomy or no other treatment. The development of cytotoxicity was dependent only upon treatment with tumour D23, and the development of blocking activity was dependent only upon whether the tumour was suppressed or allowed to grow. BCG was only effective in so far that it produced suppression of tumour cells in contact with it and splenectomy had little effect on any of the immune parameters measured, so it must be concluded that neither of these treatments affected the in vitro measurements per se.
